Characterization and in vitro cellular activity assessment of photodynamic composite nanocarriers for gliomas treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (23)
Show source-provided references
1. Pradhan A, Mozaffari K, Ghodrati F, Everson RG, Yang I (2022) Modern surgical management of incidental gliomas. J Neurooncol 159:81–9410.1007/s11060-022-04045-0 ↗
2. Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM (2019) Immunotherapy against gliomas: is the breakthrough near? Drugs 79:1839–184810.1007/s40265-019-01203-z ↗
3. Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS (2020) Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer 20:57–7010.1038/s41568-019-0226-5 ↗
4. Alsalloum A, Shevchenko JA, Sennikov S (2023) The melanoma-associated antigen family a (MAGE-A): a promising target for cancer immunotherapy? Cancers (Basel) 15:177910.3390/cancers15061779 ↗
5. Trippel A, Halling F, Heymann P, Ayna M, Al-Nawas B, Ziebart T (2019) The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis. Oral Maxillofac Surg 23:343–35210.1007/s10006-019-00778-x ↗
6. Gao X, Chen G, Cai H, Wang X, Song K, Liu L, Qiu T, He Y (2020) Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway. Biomed Pharmacother 122:109710
7. Poojary M, Jishnu PV, Kabekkodu SP (2020) Prognostic value of melanoma-associated antigen-a (MAGE-A) gene expression in various human cancers: a systematic review and meta-analysis of 7428 patients and 44 studies. Mol Diagn Ther 24:537–55510.1007/s40291-020-00476-5 ↗
8. Filippone EJ, Farber JL (2016) Membranous nephropathy in the kidney allograft. Clin Transplant 30:1394–140210.1111/ctr.12847 ↗
9. Hao YJ, An XL, Sun HD, Piao XC, Gao R, Lian ML (2020) Ginsenoside synthesis of adventitious roots in Panax ginseng is promoted by fungal suspension homogenate of Alternaria panax and regulated by several signaling molecules. Ind Crop Prod 150:112414
10. Hsieh CT, Ariga K, Shrestha LK, Hsu SH (2021) Development of MOF reinforcement for structural stability and toughness enhancement of biodegradable bioinks. Biomacromol 22:1053–106410.1021/acs.biomac.0c00920 ↗
11. Li L, Zhu Y, Qi Z, Li X, Pan H, Liu B, Liu Y (2023) GCMC simulations to study the potential of MOFs as drug delivery vehicles. Appl Organomet Chem 37:e7199
12. Kazemi A, Afshari MH, Baesmat H, Manteghi F, Nabipour H, Rohani S, Saeb MR (2024) Tunable Zn-MOF-74 nanocarriers coated with sodium alginate as versatile drug carriers. Polym Bull 81:15235–1525110.1007/s00289-024-05426-3 ↗
13. Lawson S, Siemers A, Kostlenick J, Al-Naddaf Q, Newport K, Rownaghi AA, Rezaei F (2021) Mixing Mg-MOF-74 with Zn-MOF-74: a facile pathway of controlling the pharmacokinetic release rate of curcumin. ACS Appl Bio Mater 4:6874–688010.1021/acsabm.1c00585 ↗
14. Park K, Skidmore S, Hadar J, Garner J, Park H, Otte A, Soh BK, Yoon G, Yu D, Yun Y (2019) Injectable, long-acting PLGA formulations: analyzing PLGA and understanding microparticle formation. J Control Release 304:125–13410.1016/j.jconrel.2019.05.003 ↗
15. Peleg Y, Bomback AS, Canetta PA, Radhakrishnan J, Appel GB, Ahn W (2021) Late relapses of membranous nephropathy: a case series. Kidney360 2:974–98210.34067/KID.0007712020 ↗
16. Ronco P, Debiec H (2020) Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol 15:287–31310.1146/annurev-pathol-020117-043811 ↗
17. Säemann MD, Odler B, Windpessl M, Regele H, Eller K, Neumann I, Rudnicki M, Gauckler P, Kronbichler A, Knechtelsdorfer M (2023) Diagnostik und Therapie der Membranösen Nephropathie – 2023. Wien klin Wochenschr 135:648–65510.1007/s00508-023-02261-w ↗
18. Sealfon R, Mariani L, Avila-Casado C, Nair V, Menon R, Funk J, Wong A, Lerner G, Hayashi N, Troyanskaya O (2022) Molecular characterization of membranous nephropathy. J Am Soc Nephrol 33:1208–122110.1681/ASN.2021060784 ↗
19. Sethi S, Madden B (2023) Mapping antigens of membranous nephropathy: almost there. Kidney Int 103:469–47210.1016/j.kint.2023.01.003 ↗
20. Steinman NY, Haim-Zada M, Goldstein IA, Goldberg AH, Haber T, Berlin JM, Domb AJ (2019) Effect of PLGA block molecular weight on gelling temperature of PLGA-PEG-PLGA thermoresponsive copolymers. J Polym Sci Pol Chem 57:35–3910.1002/pola.29275 ↗
21. Tian M, Li LN, Zheng RR, Yang L, Wang ZT (2020) Advances on hormone-like activity of Panax ginseng and ginsenosides. Chin J Nat Medicines 18:526–53510.1016/S1875-5364(20)30063-7 ↗
22. Wang J, Chen H, Gao J, Guo J, Zhao X, Zhou Y (2018) Ginsenosides and ginsenosidases in the pathobiology of ginseng-Cylindrocarpon destructans (Zinss) Scholten. Plant Physiol Bioch 123:406–41310.1016/j.plaphy.2017.12.038 ↗
23. Zhang H, Li Q, Liu R, Zhang X, Li Z, Luan Y (2018) A Versatile prodrug strategy to In Situ encapsulate drugs in MOF nanocarriers: a case of Cytarabine-IR820 prodrug encapsulated ZIF-8 toward chemo-photothermal therapy. Adv Funct Mater 28:180283010.1002/adfm.201802830 ↗